Aura Biosciences, Inc. (NASDAQ:AURA) Shares Sold by Fmr LLC

Fmr LLC lowered its stake in shares of Aura Biosciences, Inc. (NASDAQ:AURA) by 56.1% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 101,217 shares of the company’s stock after selling 129,234 shares during the quarter. Fmr LLC owned about 0.20% of Aura Biosciences worth $902,000 as of its most recent SEC filing.

Several other hedge funds have also recently modified their holdings of the stock. Long Focus Capital Management LLC grew its position in Aura Biosciences by 113.4% during the 2nd quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock worth $7,992,000 after purchasing an additional 561,766 shares during the last quarter. Levin Capital Strategies L.P. raised its stake in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock worth $2,476,000 after acquiring an additional 216,266 shares during the last quarter. Dimensional Fund Advisors LP raised its stake in Aura Biosciences by 20.0% in the 2nd quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after acquiring an additional 41,711 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Aura Biosciences by 51.4% during the 2nd quarter. Bank of New York Mellon Corp now owns 143,027 shares of the company’s stock worth $1,081,000 after acquiring an additional 48,549 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its stake in Aura Biosciences by 2.7% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 138,356 shares of the company’s stock valued at $1,233,000 after purchasing an additional 3,612 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Insider Buying and Selling

In other news, insider Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock in a transaction dated Friday, October 18th. The shares were sold at an average price of $12.04, for a total value of $300,903.68. Following the sale, the insider now owns 329,847 shares in the company, valued at $3,971,357.88. This trade represents a 7.04 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Janet Jill Hopkins sold 11,822 shares of the company’s stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.36, for a total transaction of $110,653.92. Following the transaction, the insider now owns 151,693 shares of the company’s stock, valued at approximately $1,419,846.48. This trade represents a 7.23 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 79,081 shares of company stock valued at $891,353. 5.40% of the stock is owned by company insiders.

Aura Biosciences Price Performance

NASDAQ:AURA opened at $8.89 on Tuesday. The company has a 50 day moving average price of $9.70 and a 200-day moving average price of $8.75. Aura Biosciences, Inc. has a 1-year low of $6.63 and a 1-year high of $12.38. The firm has a market cap of $444.06 million, a price-to-earnings ratio of -5.14 and a beta of 0.26.

Aura Biosciences (NASDAQ:AURA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.42) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.02. On average, sell-side analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on AURA. BTIG Research raised their price objective on Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a research note on Friday, October 18th. HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Aura Biosciences in a research note on Thursday, November 14th. Scotiabank increased their price objective on shares of Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a research note on Friday, October 18th. Evercore ISI raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Finally, Lifesci Capital raised shares of Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, Aura Biosciences has a consensus rating of “Buy” and an average target price of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.